Dr. Nicholas Medendorp, Jr. Named CEO of PhotonMD, Inc.

DURHAM, N.C., Mar. 9, 2017 -- KNOW Bio, LLC., a leading innovator in healthcare, today announced the debut of PhotonMD, Inc., their new medical device business. It is led by Dr. Nicholas Medendorp, Jr, who serves as President and Chief Executive Officer.
 Medendorp, founder of PhotonMD, is a seasoned technology and product development leader with more than 80 US patents in LED and lighting products. He has more than 19 years of experience in the technology development industry and has served in a broad range of functions, including electro-optics, product development, manufacturing and marketing. In addition, he has extensive experience in developing companies to high growth and profitability, including senior leadership roles with start-ups and large technology companies.
 "We started PhotonMD with one simple goal: to improve peoples’ lives using tailored photomedicine products. And to that end, we are focused on the development of medical devices that target therapeutic solutions for aesthetic applications, chronic inflammatory diseases, and other conditions susceptible to light-based healing,” said Dr. Medendorp.
 “Nick Medendorp brings a very diverse technology knowledge base and is highly skilled at building strong teams.  Nick’s passion and tenacity are positioning PhotonMD as a dominant player in the photomedicine device market,” said Neal Hunter, Chairman of KNOW Bio, LLC.
 Most recently, Medendorp served as Vice President, Medical Devices at Novan, Inc (NASDAQ: NOVN) where he led the team responsible for the creation and development of medical devices.  This group, which was the foundation for PhotonMD, was included in the separation of assets in late 2015 prior to Novan taking the medical dermatology business public.  Previously, Nick served as Vice President of Research and Development and Vice President of Operations at Cree, Inc. where he focused on building teams that accelerated LED technology development and deployment in commercial and industrial applications. He earned a B.S., M.S. and Ph.D. in Materials Engineering from Purdue University.
 “I am proud of the world class team we have assembled that has more than 65 years of product development experience, medical device commercialization, and has been involved in more than 50 device clearances. I look forward to our team accelerating recent advancements in the understanding of the biological responses to light and improvements in the digitization and selectivity of light-based technologies,” Medendorp said.
 About PhotonMDPhotonMD’s Modulated Light Therapy (MLTTM) technology is based on a photomedicine platform that can be delivered in a variety of doses and tailored form factors for specific indications. KNOW Bio, LLC was created to develop and optimize biotechnology solutions for many different applications. For more information, please visit www.photonmd.com.
 Forward-looking StatementsExcept for historical information, all the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: reliance on key personnel; the early stage of our business; risks associated with the medical device and drug development processes; competition; and other risks described in other Company press releases and presentations. KNOW Bio and PhotonMD assumes no obligation and do not intend to update these forward-looking statements, except as required by law.

Around the web

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Trimed Popup
Trimed Popup